The remarkable achievements of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway in the clinical tumor immunotherapy have attracted great attention to immune checkpoint blockade therapy, and also laid a foundation for its further application in the treatment of other immune-related diseases. The gene discussed is PDCD1; the disease is neoplasm.